Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT

• Status: Recruiting
• Trial end date: 2025-04-14
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety and tolerability of HMPL-653 in patients with advanced solid tumors who have failure of standard of care or can not tolerate standard of care or those with TGCT, and to determine the maximum tolerated dose (MTD) and/or the recommended phase II clinical study dose (RP2D) of HMPL-653 in patients with advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hutchison Medipharma Limited

Criteria

Inclusion Criteria:

1. Able to understand and willing to sign the ICF.

2. Aged 18 to 75 years.

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

4. Life expectancy at least 12 weeks.

5. Adequate bone marrow, liver and kidney function.

Exclusion Criteria:

1. Toxicity associated with previous antitumor therapy not recovered to ≤CTCAE grade 1；

2. Previous treatment with anti-CSF1R therapy and have progressive disease;

3. Receiving approved systematic antitumor therapy or in the treatment period of other interventional clinical study within 4 weeks prior to the first dose.

4. Patients with central nervous system (CNS) malignant tumor or malignant solid tumor with known CNS metastasis;

5. Pregnant or lactating women.